Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDORIL 25 vs ALORA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
Hypertension
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative),Breast cancer (palliative, in selected cases),Postpartum breast engorgement (prevention)
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). Not studied in severe impairment (GFR <30 m L/min); use with caution.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A).
Not established; avoid use in children.
Not approved for use in pediatric patients. Safety and efficacy not established.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed.
None
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease, known protein C/protein S/antithrombin deficiency or other thrombophilic disorders, liver dysfunction or disease, known hypersensitivity to estradiol or any component.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Estradiol is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. ALORA may reduce milk production and quality due to estrogenic effects. Use during breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure such as breast enlargement or vaginal bleeding.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
ALORA is contraindicated in pregnancy; no dosing adjustments are applicable. The physiological increase in estrogen-binding proteins and hepatic clearance during pregnancy would theoretically reduce efficacy if used, but use is prohibited due to teratogenicity.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
Use the measured applicator for correct dose.,Apply cream at bedtime for best absorption.,Wash applicator after each use with soap and water.,Report any abnormal vaginal bleeding immediately.,Do not use if allergic to estrogens.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDORIL 25 vs ALORA, answered by our medical review team.
ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. ALORA is a Estrogen that works by Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDORIL 25 and ALORA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. The standard adult dose of ALORA is: Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDORIL 25 and ALORA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. ALORA is classified as Category C. ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.